Valuation: Corcept Therapeutics Incorporated

Market Cap 12.87B 11.04B 10.31B 9.46B 17.78B 1,230B 18.07B 122B 47.62B 617B 48.31B 47.26B 2,039B P/E 2026 *
57.8x
P/E 2027 * 27.7x
Enterprise Value 12.87B 11.04B 10.31B 9.46B 17.78B 1,230B 18.07B 122B 47.62B 617B 48.31B 47.26B 2,039B EV / Sales 2026 *
11.2x
EV / Sales 2027 * 7.55x
Free-Float
65.9%
Yield 2026 *
-
Yield 2027 * -
1 day+0.78%
1 week+6.10%
Current month+3.96%
1 month+31.48%
3 months+104.43%
6 months+247.61%
Current year+242.01%
1 week 110.08
Extreme 110.085
121.11
1 month 90
Extreme 90
122.21
Current year 28.66
Extreme 28.6601
122.21
1 year 28.66
Extreme 28.6601
122.21
3 years 20.84
Extreme 20.84
122.21
5 years 15.82
Extreme 15.825
122.21
10 years 5.24
Extreme 5.24
122.21
Manager TitleAgeSince
Chief Executive Officer 68 1998-12-31
Director of Finance/CFO 49 2021-02-28
Chief Tech/Sci/R&D Officer 48 2024-01-31
Director TitleAgeSince
Director/Board Member 68 1998-12-31
Chairman 82 1998-12-31
Director/Board Member 71 2004-06-30
Date Insider Type Main position Quantity % Market Cap.
8/12/26 Don

Company Secretary

-17,530 0.0162%
8/10/26 Fiscal year

Executive/Senior Manager

3,093 0.0029%
8/10/26 Fiscal year

Executive/Senior Manager

48,900 0.0452%
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%+6.10%+69.57%+284.80% 12.77B
+4.46%+4.92%+82.07%+134.31% 1,093B
+0.85%+4.81%+53.77%+58.51% 653B
+2.72%+6.92%+28.99%+77.15% 458B
+1.80%+0.52%+41.20%+44.05% 355B
+1.24%+2.35%+25.99%+42.21% 294B
+2.07%+2.97%+2.27%+13.06% 248B
+4.02%+6.29%+49.67%+68.96% 230B
+1.05%-0.02%-13.96%-52.13% 203B
+2.90%+8.63%+25.11%+94.52% 178B
Average +1.81%+3.42%+36.47%+76.54% 372.32B
Weighted average by Cap. +1.53%+3.66%+46.95%+74.46%

Financials

2026 *2027 *
Net sales 1.15B 983M 918M 842M 1.58B 110B 1.61B 10.83B 4.24B 54.94B 4.3B 4.21B 182B 1.7B 1.46B 1.37B 1.25B 2.36B 163B 2.39B 16.11B 6.31B 81.73B 6.4B 6.26B 270B
Net income 242M 207M 193M 178M 334M 23.09B 339M 2.28B 894M 11.58B 907M 887M 38.28B 594M 509M 475M 436M 820M 56.74B 834M 5.61B 2.2B 28.46B 2.23B 2.18B 94.09B
Net Debt - -
Logo Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.
Employees
730
Date Price Change Volume
26-08-19 US$119.02 +0.78% 859,630
26-08-18 US$118.10 +0.79% 804,025
26-08-17 US$117.17 +2.36% 541,103
26-08-14 US$114.47 +3.58% 728,923
26-08-13 US$110.51 -1.49% 740,456
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
119.02USD
Average target price
141.00USD
Spread / Average Target
+18.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CORT Stock